Completed dosing in Phase 1b challenge study of Cdi-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary efficacy results expected near the end of 2026 Closed 5 million private pl
Cocrystal Pharma, Inc. (COCP) — Live Session & Technical Brief
Updated Nov 16, 2026 2:41 PM ET · Prev Close $0.98
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (+1.98%) in Biotechnology
Cocrystal Pharma, Inc. (COCP) is trading within a tight intraday band at $1.00 (+1.98%, 0.80x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, COCP is outperforming the S&P 500 by +3.87%. 14-day RSI stands at 46.3, keeping momentum in a bearish regime.
Completed dosing in Phase 1b challenge study of Cdi-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary efficacy results expected near the end of 2026 Closed 5 million private pl
Price ($1.00) trades relative to 20-day SMA ($1.00) and 50-day SMA ($1.08).
Market & Sector Relative Strength
COCP outperforming the S&P 500 by +3.87%Recent COCP Catalyst Headlines
Verified WireJames Sapirstein is bringing his Big Pharma chops to the clinical-stage company s efforts to finally deliver an effective treatment for the vexing stomach bug.
No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 Miami, Fla. And Bothell, Wash., Sept. 09, 2026 Globe Newswire -- Cocrystal Pharma, Inc. Nasdaq COCP Cocrystal or
By Mike Sheikh Cocrystal Pharma Nasdaq Cocp may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Invest
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $1.00 (20-day SMA support) for directional breakout confirmation.
Technical Regime (COCP)
MIXED MA TRENDRetail & Crowd Sentiment
Very BullishStockTwits is filled with bullish messages about $COCP with no new news articles available.
About Cocrystal Pharma, Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing Cc-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor …
Get Instant COCP Catalyst Alerts
Receive an email alert when COCP triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversCOCP Session & Catalyst FAQ
Why is COCP stock trading near flat today?
Cocrystal Pharma, Inc. (COCP) is trading within a tight intraday band at $1.00 (+1.98%, 0.80x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, COCP is outperforming the S&P 500 by +3.87%. 14-day RSI stands at 46.3, keeping momentum in a bearish regime.
Is COCP stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.80x relative volume (low participation). Our multi-factor model currently rates COCP as HOLD. Review full valuation, quality, and timing signals on the COCP Buy or Sell Decision Brief →
What is COCP's intrinsic value and expected trading range?
At $1.00, COCP's modeled 1-to-3 session range is $0.96 – $1.04, with a key inflection level at $1.00 (20-day SMA support). Compare current price against multi-year cash flow projections in the COCP Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for COCP?
RSI at 46.3 reflects soft below-midline momentum. COCP trades at $1.00 relative to its 20-day SMA ($1.00) and 50-day SMA ($1.08), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.